Navigation Links
Accuray Hires Chief Financial Officer
Date:12/4/2008

SUNNYVALE, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company has hired Derek Bertocci as its chief financial officer.

Bertocci, who has been serving as the chief financial officer of BioForm Medical, Inc., a publicly-traded medical aesthetics company headquartered in San Mateo, Calif., since October 2006, will begin at Accuray on January 1, 2009.

"We are very pleased to have someone with Derek's experience join the Accuray management team," said Euan S. Thomson, Ph.D., president and CEO of Accuray Incorporated. "His established track record in the financial management of leading medical device and surgical companies will add tremendous value to our business."

Bertocci served as the chief financial officer of BioForm Medical since October 2006 and added the title of corporate secretary in July 2007. From June 2005 to July 2006, he was chief financial officer of Laserscope, a publicly traded provider of lasers and fiber optic devices for urology and aesthetic surgery. From March 2004 to May 2005, Bertocci served as chief financial officer of VISX Incorporated, a publicly traded provider of systems for laser vision correction surgery and from 1998 to March 2004, he served as vice president and controller of VISX.

Bertocci earned his Certified Public Accountant (CPA) certification while working for PricewaterhouseCoopers. He holds a B.A. from Stanford University and an M.B.A. from the University of Southern California.

Holly Grey, who was serving as the company's interim principal financial officer, will return to her role as Accuray's senior vice president of finance.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently more than 145 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the year ended June 30, 2008 as updated from time to time by our quarterly reports on Form 10-Q, our Form 12b-25 dated November 7, 2008, our Form 8-K dated November 20, 2008, and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Accuray Incorporated to Present at 20th Annual Piper Jaffray Health Care Conference
2. Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q
3. Accuray Incorporated Ranked Fifth in Deloittes Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies
4. Accuray Incorporated to Speak at Oppenheimer Healthcare Conference
5. Accuray Incorporated to Report First Quarter Fiscal Year 2009 Financial Results
6. Accuray Incorporated Announces Resignation of Chief Financial Officer
7. Accuray Incorporated to Report Fourth Quarter and Fiscal Year 2008 Financial Results
8. Accuray Incorporateds CEO to Speak at Jefferies Second Annual Healthcare Conference
9. Accuray Incorporateds CEO to Present at Morgan Stanley 2008 Global Healthcare Unplugged Conference
10. Accuray Incorporated to Report Third Quarter Fiscal Year 2008 Financial Results
11. Accurays CFO to Present at B. Riley & Company Ninth Annual Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... ... announced a new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies ... quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral fat, also known as ... kidneys, liver and pancreas. If not properly addressed, visceral fat can lead to ... Medicine, Medical Oncology and Palliative Care, warns against the dangers of visceral fat. ...
(Date:5/2/2016)... (PRWEB) , ... May 02, ... ... researchers report that many commonly used prescription medications, including anxiolytics, painkillers, antidepressants ... mitigate these risks, Novus Medical Detox Center —a leading Florida-based drug ...
(Date:5/2/2016)... , ... May 02, 2016 , ... Pregnancy Awareness Month ... trying to conceive. , “If you are ready to have a baby, ... “My book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy Organizer, written ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... and urgent care facilities designed to automate and improve the rapid diagnosis, triage ... it is demonstrating their platform, application, and mobile experience for the first time ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... 2016 New market research ... a report that provides an overview of the ... by identifying new targets and MOAs to produce ... discussed in this H1 2016 Osteoarthritis Pipeline report ... Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, ...
(Date:4/27/2016)... 2016   ... sur le trimestre, soutenu par une croissance de ... Croissance de +16% des ventes aux hôpitaux et ... Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de ... son chiffre d,affaires pour le premier trimestre clos ...
Breaking Medicine Technology: